Physalaemin
An oligopeptide isolated from the skin of Physalaemus fuscumaculatus, a South American frog. It is a typical kinin, resembling SUBSTANCE P in structure and action and has been proposed as a sialagogue, antihypertensive, and vasodilator.
Also Known As:
Physalemin
Networked: 11
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Chromosome Aberrations (Chromosome Abnormalities)
|
2. | Small Cell Carcinoma
|
3. | Neoplasms (Cancer)
01/07/1983
- " Both physalaemin and the tumor peptide produced a contractile response of isolated guinea pig ileum at threshold concentrations of approximately 100 to 150 picograms per milliliter. " 01/07/1983
- " Tumor-related peptide cross-reacted with three antiserums to physalaemin to yield 1.1 to 1.6 nanomoles per gram of tissue. " 02/01/1994
- " In contrast, TNT-1/IL-1 and TNT-1/TNF produced a combination of effects, and TNT-1/leukotriene B4, TNT-1/bradykinin, and TNT-1/physalaemin affected only tumor blood volume. " 02/01/1994
- " TNT-1/IL-2 gave the highest percent injected dose/g in tumor (4.80), compared with TNT-1/TNF (4.00), TNT-1/IL-1 (3.83), TNT-1/leukotriene-B4 (2.84), TNT-1/histamine (2.80), TNT-1/physalaemin (2.19), TNT-1/bradykinin (1.57), or TNT-1 alone (1.28). " 01/07/1983
- " Physalaemin and tumor peptide had similar retention times on high-performance liquid chromatography after chemical and enzymic modifications that included pH changes, oxone oxidation, use of a hydrophilic ion-pairing reagent, and digestion with trypsin and pyroglutamate aminopeptidase. "
|
4. | Carcinoid Tumor (Carcinoid)
|
5. | Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|
|
Related Drugs and Biologics